Several anti-cancer agents are now available for mCRPC, including cytotoxic chemotherapy (docetaxel [4] and cabazitaxel [5]), androgen receptor signaling inhibitors (ARSIs) (abiraterone acetate [6] and enzalutamide [7]), poly ADP-ribose polymerase (PARP) inhibitors (olaparib [8]), radioligand therapies (radium-223 [9] and lutetium-177-PSMA-617 [10]), and cancer vaccines (sipuleucel-T [11]), although they are not curative [3,12,13]. Here, FOLH1 is linked to cancer.